Your session is about to expire
← Back to Search
LYL845 for Solid Cancers
Study Summary
This trial will test a new cancer therapy for people with melanoma, lung cancer and colorectal cancer.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had cell therapy treatment before.I have fluid buildup in my chest or abdomen that causes symptoms.I am fully active or can carry out light work.I have not had any other cancer within the last 3 years.I have a cancer lesion that can be removed and another that can be measured and biopsied.I currently have an untreated or active infection.I am capable of becoming pregnant and have a negative pregnancy test.I am between 18 and 75 years old.I am taking more than 10 mg of prednisone or its equivalent daily.I have heart problems or significant heart disease.I have no lingering side effects from previous cancer treatments.My cancer (melanoma, NSCLC, or CRC) is advanced, cannot be surgically removed, and has not responded to standard treatments.I am on long-term blood thinners like warfarin.I have had a solid organ transplant.My cancer has spread to my brain or spinal cord and is either widespread, causing symptoms, or not treated.My organs and bone marrow are working well.I am receiving treatment for an autoimmune disease or have a primary immunodeficiency.My melanoma worsened after CPI treatment and, if BRAF-mutated, after BRAF/MEK inhibitor therapy.My NSCLC worsened after treatment, including immunotherapy or targeted therapy if it was suitable.
- Group 1: Experimental LYL845
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What safety protocols have been implemented to ensure the usage of Experimental LYL845 is not detrimental?
"Our team's assessment of the safety profile of Experimental LYL845 is a 1 due to its phase 1 status, which indicates that there is limited data available on both efficacy and safety."
Am I eligible to partake in this research project?
"This clinical trial is accepting 108 individuals diagnosed with colorectal carcinoma, aged between 18 and 75. Participants must meet the following requirements: have attained age of consent or be older, possess a verified diagnosis of melanoma, non-small cell lung cancer (NSCLC), or colorectal cancer that has metastasized/is locally advanced/cannot be surgically removed, demonstrate measurable disease along with an accessible lesion to measure response and another for biopsy purposes, present ECOG performance status 0 or 1; show adequate organ & marrow function; female subjects should perform pregnancy test prior to admission; all participants need"
What are the anticipated outcomes of this investigation?
"According to the sponsor of this trial, Lyell Immunopharma, Inc., its primary goal is to Determine recommended Phase 2 Dose Range (RP2DR) over a two year period. Additionally, secondary objectives include evaluation of anti-tumor activity via Complete response rate (CR) by RECIST version 1.1 , assessment of Overall survival (OS), and T-cell phenotype assay using flow cytometry and RNA expression profiling for LYL845."
Are there several venues across Canada which are hosting this trial?
"Four medical centres are currently participating in this research initiative, such as the Huntsman Cancer Institute at University of Utah in Salt Lake City, Allegheny General Hospital in Pittsburgh, and Oregon Health Sciences University in Portland. Additionally, there is a quartet of other locations available for enrolment."
Is eligibility for this medical study restricted to a particular age group?
"As per the parameters outlined in the eligibility criteria, would-be participants of this clinical trial must be between 18 and 75 years old."
Are there still opportunities to join this research project?
"This research, first posted on December 1st 2022 and last revised October 11th of the same year, is no longer in search of participants. Nonetheless, there are 3,054 other medical trials that are actively seeking enrollees at this moment."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger